Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.

Employees

2,680

Sector

Biotechnology & Medical Research

Calendar

03-24 - Annual General Meeting

More about the company

Quotes

Date	Price	Change	Volume
13/02/26	238,000.00 ₩	-0.21%	672,153
12/02/26	238,500.00 ₩	-0.42%	952,461
11/02/26	239,500.00 ₩	+5.27%	1,723,596
10/02/26	227,500.00 ₩	-1.09%	621,686
09/02/26	230,000.00 ₩	+4.55%	1,603,024

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

238,000.00KRW

Average target price

251,521.74KRW

Spread / Average Target

+5.68%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

End-of-day quote Korea S.E. Other stock markets 13/02/2026			5-day change	1st Jan Change
238,000.00 ^KRW	-0.21%		+8.18%	+31.49%

02-05	CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5)	RE
01-30	Celltrion Launches Autoimmune Drug Aptozma in Europe	MT

Capitalization	52,094B 36.15B 30.48B 27.77B 26.52B 49.23B 3,274B 51.16B 323B 128B 1,579B 136B 133B 5,531B	P/E ratio 2025 *	63.2x	P/E ratio 2026 *	40x
Enterprise value	53.4B 37.06M 31.24M 28.46M 27.18M 50.46M 3.36B 52.44M 331M 131M 1.62B 139M 136M 5.67B	EV / Sales 2025	9.51x	EV / Sales 2026 *	10.2x
Free-Float	70.87%	Yield 2025 *	0.3%	Yield 2026 *	0.3%

02-05	CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5)	RE
01-30	Celltrion Launches Autoimmune Drug Aptozma in Europe	MT
01-14	Celltrion Presents Innovative Drug Pipeline and U.S. Manufacturing and R&D Expansion Strategy At the 44Th Annual J.P. Morgan Healthcare Conference	CI
01-06	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance	MT
01-06	Abpro Holdings, Inc. and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	CI
01-03	Health Care Up on Anti-Obesity Drug Sales Outlook - Health Care Roundup	DJ
01-02	Celltrion, Inc. acquired Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY).	CI
01-02	Celltrion Shares Rally on U.S. Contract, Earnings Outlook	DJ
01-02	Celltrion Inc U.S. unit Celltrion USA signs production contract with Eli Lilly worth 473 million USD	RE
12-22	Samsung Biologics to buy US drug production facility from GSK for $280 million	RE
12-18	Celltrion, Inc. Receives Positive CHMP Opinion for SteQeyma (Uustekinumab Biosimilar) Autoinjector	CI
12-15	Abpro Holdings, Inc. and Celltrion, Inc. Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-Positive Cancers	CI
12-11	Celltrion USA, Inc. announced that it expects to receive $532.1 million in funding from Celltrion, Inc.	CI

17/03/25	Nomura Adjusts Celltrion's Price Target to KRW240,000 From KRW230,000, Keeps at Buy	MT
27/06/22	Celltrion Wins Sales Approval Recommendation For Its CT-P16 From European Medicines Agency's Committee	RE

Celltrion, Inc. Stock

Equities

A068270

KR7068270008

Biotechnology & Medical Research

Valuation: Celltrion, Inc.

Chart: Celltrion, Inc.

Latest news: Celltrion, Inc.

Analysts' recommendations: Celltrion, Inc.

Press Releases: Celltrion, Inc.

News in other languages: Celltrion, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Celltrion, Inc.

ETFs: Celltrion, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

02-12	Celltrion : to Submit Approx KRW 1.46Tn Treasury Share Cancellation Proposal to Shareholders’ Meeting; To Amend Articles Ahead of Commercial Act Revision to Enhance Transparency and Shareholder Value	PU
02-05	Celltrion : Reports Record-High Annual Revenue of KRW 4.1625Tn and Operating Profit of KRW 1.1685Tn in 2025… Signaling Continued Strong Growth Backed by High-Margin Newer Portfolio	PU
01-08	Celltrion And Sandoz Launch Their Aflibercept Biosimilars In Europe	AQ
11-05	FDA Grants Interchangeability Designation To Fresenius Kabi's And Celltrion's Denosumab Biosimilars	AQ
14/10/25	Celltrion Announces Launch Of AVTOZMA® (Tocilizumab-anoh) Intravenous Formulation In The United States	AQ

01-30	Bourse : les midcaps au pouvoir à Paris, Sandisk flambe, Adidas assure, Swatch déçoit, mais…
01-30	Les premiers seront les derniers, mais pas sûr
24/09/25	Wall Street : La Fed ne peut pas sauver tout le monde
23/09/25	Wall Street: la confiance en suspens jusqu'à la prise de parole de Powell
10/03/25	US-Behörde FDA lässt Biosimilar für Roche-Mittel Xolair zu

1 day	-0.21%
1 week	+8.18%
Current month	+13.33%
1 month	+12.53%
3 months	+21.37%
6 months	+36.00%
Current year	+31.49%

1 week	224,500	243,500
1 month	200,500	243,500
Current year	188,600	243,500
1 year	144,615.38	243,500
3 years	119,963.37	243,500
5 years	119,963.37	289,625.22
10 years	65,004.08	341,497.26

Manager	Title	Age	Since
Wu-Sung Ki CEO	Chief Executive Officer	-	20/03/2015
Ho-Seop Lee DFI	Director of Finance/CFO	51	-
Sung-Han Lee CMP	Compliance Officer	44	-

Director	Title	Age	Since
Jung-Jin Seo CHM	Chairman	68	-
Dong-Il Kim BRD	Director/Board Member	67	17/07/2008
Joseph Lee BRD	Director/Board Member	67	17/07/2008

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
CELLTRION, INC.	-0.21%	+8.18%	+36.90%	+61.03%	36.11B
LONZA GROUP AG	+4.62%	+0.73%	-12.50%	-4.72%	47.61B
BEONE MEDICINES AG	-0.10%	-2.22%	+49.90%	+43.32%	38.3B
IQVIA HOLDINGS INC.	-1.13%	-10.96%	-13.70%	-26.48%	28.31B
REVOLUTION MEDICINES, INC.	-1.05%	-1.21%	+136.81%	+277.83%	18.62B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	+7.58%	+14.65%	+31,531.21%	+4,137.24%	15.44B
EUROFINS SCIENTIFIC SE	+2.25%	-3.74%	+31.21%	-3.02%	13.71B
ASCENDIS PHARMA A/S	-0.82%	-2.62%	+50.14%	+94.88%	13.28B
IONIS PHARMACEUTICALS, INC.	-1.44%	-6.82%	+159.66%	+105.56%	13.06B
MEDPACE HOLDINGS, INC.	+2.88%	-21.03%	+25.83%	+97.13%	12.15B
Average	+1.26%	-2.97%	+3,199.55%	+478.28%	23.66B
Weighted average by Cap.	+1.31%	-1.95%	+2,092.69%	+320.02%

	2025	2026 *
Net sales	4,141B 2.87B 2.42B 2.21B 2.11B 3.91B 260B 4.07B 25.66B 10.19B 126B 10.78B 10.56B 440B	5,219B 3.62B 3.05B 2.78B 2.66B 4.93B 328B 5.12B 32.34B 12.84B 158B 13.59B 13.31B 554B
Net income	867B 601M 507M 462M 441M 819M 54.45B 851M 5.37B 2.13B 26.27B 2.26B 2.21B 92.01B	1,374B 954M 804M 732M 699M 1.3B 86.35B 1.35B 8.52B 3.38B 41.66B 3.58B 3.5B 146B
Net Debt	1,304B 905M 763M 695M 664M 1.23B 81.93B 1.28B 8.08B 3.21B 39.53B 3.4B 3.32B 138B	1,044B 725M 611M 557M 532M 987M 65.63B 1.03B 6.47B 2.57B 31.66B 2.72B 2.66B 111B